Pharmacogenetics Roll Out - Gauging Response to Service (PROGRESS)
Research type
Research Study
Full title
Pharmacogenetics Roll Out - Gauging Response to Service (PROGRESS)
IRAS ID
319800
Contact name
William Newman
Contact email
Sponsor organisation
Manchester University NHS Foundation Trust
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
There is growing understanding that the effectiveness and safety of many regularly prescribed medications can be influenced by common genetic changes. This is a concept known as pharmacogenetics. Although there are guidelines in place for genotype-guided prescribing for many gene-drug pairs, very few are used in practice as previously, genetic testing could not be turned around in a clinically relevant timeframe.
The PROGRESS trial is part of a programme of work to introduce pharmacogenetic testing in general practice and to assess the implementation of this new service. A panel of genes with known implications for a range of commonly prescribed medicines has been selected and an informatic solution to help guide prescribing has been developed called the Genomic Prescribing Advisory System (GPAS). This pharmacogenetic testing and advisory system will be implemented at a number of GP practices to establish whether genetic testing can be delivered to support genotype guided prescribing in a clinically relevant timeframe.
The study is recruiting over two phases. In phase one (months 1-6), five “early-adopter” sites will invite patients who are being considered for 4 classes of medicine as part of their routine appointment. These medicines include Statins, Proton Pump Inhibitors, Selective Serotonin Reuptake Inhibitors, and Tricyclic Antidepressants. Participants would be required to donate a blood or saliva sample for genetic testing, with the aim to return results to the GP within 7-10 days. Patients will be alerted by their GP once results are available and a prescription can be issued. In the second phase (months 7-18), additional sites across the country will be included.
The study is designed to identify any challenges in implementing this service as well as collect information on patient and health care professional’s attitudes to using the service.
REC name
London - Surrey Research Ethics Committee
REC reference
23/LO/0201
Date of REC Opinion
15 Mar 2023
REC opinion
Favourable Opinion